The firm expects to begin the Phase I trial in HER2-positive breast and gastric cancers in the first half of 2026.
The company plans to launch a Phase I trial of its lead autologous cell therapy for renal cell carcinoma in 2026.
The nonprofit subsidiary Orphan Therapies will be the exclusive commercializaiton partner for the Wiskott-Aldrich syndrome gene therapy in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback